Varicella vaccination in Europe - taking the practical approach by Bonanni, P et al.
BioMed CentralBMC Medicine
ssOpen AcceReview
Varicella vaccination in Europe – taking the practical approach
Paolo Bonanni1, Judith Breuer2, Anne Gershon3, Michael Gershon4, 
Waleria Hryniewicz5, Vana Papaevangelou6, Bernard Rentier7, Hans Rümke8, 
Catherine Sadzot-Delvaux*7, Jacques Senterre9, Catherine Weil-Olivier10 and 
Peter Wutzler11
Address: 1Department of Public Health, University of Florence, Florence, Italy, 2Skin Virus Laboratory, Centre for Cutaneous Research, St 
Bartholomew's and The Royal London School of Medicine and Dentistry, Queen Mary College, London, UK, 3Department of Pediatrics, Columbia 
University College of Physicians and Surgeons, New York, USA, 4Department of Pathology and Cell Biology, Columbia University College of 
Physicians and Surgeons, New York, USA, 5National Medicines Institute, Chelmska Street, 00-725 Warsaw, Poland, 6Second Department of 
Pediatrics, University of Athens Medical School, "P & A Kyriakou" Children's Hospital, Athens, Greece, 7Unit of Fundamental Virology and 
Immunology, GIGA-Research, B34 University of Liége, 4000 Liège, Belgium, 8Vaxinostics, University Vaccine Center Rotterdam Nijmegen, 
Rotterdam, the Netherlands, 9Department of Pediatrics, University of Liège, Liège, Belgium, 10University Paris VII, Paris 75005, France and 
11Institute of Virology and Antiviral Therapy, Friedrich-Schiller University, Jena, Germany
Email: Paolo Bonanni - paolo.bonanni@unifi.it; Judith Breuer - j.breuer@qmul.ac.uk; Anne Gershon - aag1@columbia.edu; 
Michael Gershon - mdg4@columbia.edu; Waleria Hryniewicz - waleria@cls.edu.pl; Vana Papaevangelou - vpapaev@med.uoa.gr; 
Bernard Rentier - brentier@ulg.ac.be; Hans Rümke - rumke@vaxinostics.com; Catherine Sadzot-Delvaux* - csadzot@ulg.ac.be; 
Jacques Senterre - senterre.jacques@belgacom.net; Catherine Weil-Olivier - catweiloli@hotmail.com; Peter Wutzler - peter.wutzler@med.uni-
jena.de
* Corresponding author    
Abstract
Varicella is a common viral disease affecting almost the entire birth cohort. Although usually self-
limiting, some cases of varicella can be serious, with 2 to 6% of cases attending a general practice
resulting in complications. The hospitalisation rate for varicella in Europe ranges from 1.3 to 4.5
per 100,000 population/year and up to 10.1% of hospitalised patients report permanent or possible
permanent sequelae (for example, scarring or ataxia). However, in many countries the
epidemiology of varicella remains largely unknown or incomplete.
In countries where routine childhood vaccination against varicella has been implemented, it has had
a positive effect on disease prevention and control. Furthermore, mathematical models indicate
that this intervention strategy may provide economic benefits for the individual and society.
Despite this evidence and recommendations for varicella vaccination by official bodies such as the
World Health Organization, and scientific experts in the field, the majority of European countries
(with the exception of Germany and Greece) have delayed decisions on implementation of routine
childhood varicella vaccination, choosing instead to vaccinate high-risk groups or not to vaccinate
at all.
In this paper, members of the Working Against Varicella in Europe group consider the practicalities
of introducing routine childhood varicella vaccination in Europe, discussing the benefits and
challenges of different vaccination options (vaccination vs. no vaccination, routine vaccination of
infants vs. vaccination of susceptible adolescents or adults, two doses vs. one dose of varicella
vaccine, monovalent varicella vaccines vs. tetravalent measles, mumps, rubella and varicella
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BMC Medicine 2009, 7:26 http://www.biomedcentral.com/1741-7015/7/26vaccines, as well as the optimal interval between two doses of measles, mumps, rubella and varicella
vaccines).
Assessment of the epidemiology of varicella in Europe and evidence for the effectiveness of varicella
vaccination provides support for routine childhood programmes in Europe. Although European
countries are faced with challenges or uncertainties that may have delayed implementation of a
childhood vaccination programme, many of these concerns remain hypothetical and with new
opportunities offered by combined measles, mumps, rubella and varicella vaccines, reassessment
may be timely.
Background
Varicella is a highly contagious disease caused by the vari-
cella zoster virus (VZV), a member of the alpha herpesvi-
rus family. Varicella (or chickenpox) is characterised by a
vesicular rash, usually accompanied by fever and malaise
[1].
In 1998, the World Health Organization (WHO) recom-
mended that routine childhood varicella vaccination be
considered in countries where the disease is a relatively
important public health and socioeconomic problem,
where the vaccine is affordable, and where high (85 to
90%) and sustained vaccine coverage can be achieved [2].
More than 10 years later, the varicella vaccine is used in
childhood immunisation programmes in Australia [3],
Canada [4], Germany [5], Greece [6], Qatar [7], Republic
of Korea [8], Saudi Arabia [7], Taiwan [9], United States of
America (USA) [10], Uruguay [11] and parts of Italy (Sic-
ily) [8] and Spain (Autonomous Community of Madrid)
[12].
However, recommendations for varicella vaccination in
Europe vary, with the majority of countries not following
the WHO recommendations for universal routine vacci-
nation (URV), instead recommending vaccination of sus-
ceptible adolescents or high-risk groups. Furthermore,
despite the proven health benefits of varicella vaccination
[11,13-16], most European countries have delayed the
introduction of the vaccine into their immunisation
schedules.
This paper seeks to explore the basis of the WHO recom-
mendation in relation to the clinical epidemiology of vari-
cella in Europe, and to understand the reasons for the
recommendations not being widely adopted in this
region. The practicalities of introducing varicella vaccina-
tion into national childhood immunisation calendars in
Europe are also evaluated, including discussion on the
benefits and challenges of different schedules for mono-
valent varicella vaccines (Varilrix™, GlaxoSmithKline Bio-
logicals, Rixensart, Belgium and Varivax™ Sanofi Pasteur
MSD, Lyon, France) and for the new combination mea-
sles, mumps, rubella, varicella (MMRV) vaccines (Priorix-
Tetra™, GlaxoSmithKline Biologicals, Rixensart, Belgium
and ProQuad™, Sanofi Pasteur MSD, Lyon, France).
Why vaccinate against varicella in Europe?
The clinical epidemiology of varicella in Europe is sum-
marised in Table S1 (Additional file 1) (mortality) [17-31]
and Additional file 2 (incidence, hospitalisations and
complications) [12,17-27,29,30,32-43]. It is noteworthy
that differences in study methodology mean that epidemi-
ological information cannot be easily compared across
studies. Furthermore, the majority of studies were con-
ducted in hospitals, with few data available from non-
hospitalised patients. In many European countries, such
as Belgium and the United Kingdom (UK), the true clini-
cal impact of varicella remains to be determined because
it is not a notifiable disease. In other countries, epidemio-
logical data are available, but they may not accurately
reflect the true burden of varicella given under-reporting
to statutory notification systems [38]. For example, in
Italy, the age-standardised incidence of varicella in chil-
dren 0 to14 years of age collected from a paediatric senti-
nel network of primary care physicians was 3.8-fold
higher than that from statutory notifications (P < 0.0001)
[38].
Varicella incidence and seroprevalence
Population surveys described in Additional file 2 reveal
that varicella is a common disease in European countries
affecting nearly the entire birth cohort. For example, in
Germany there was an annual incidence of approximately
760,000 new varicella cases in a birth cohort of around
800,000 prior to widespread vaccination in 1999 [35].
In Europe, the sero-epidemiology of VZV characterises
varicella as a disease of childhood, with rapid acquisition
of antibodies to VZV during early life [24,44-52]. By ado-
lescence, the majority of individuals are seropositive for
VZV antibodies [44,45]. However, there are differences
across the European region [44]; seroprevalence appears
to be slightly lower among children in southern European
countries [51,52] than in northern or central European
countries (Table S2 in Additional file 1) [48,53], which
may be explained by different climates (Mediterranean vs.Page 2 of 12
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UK and Belgium, report a higher seroprevalence among
children younger than 4 years of age than other parts of
Europe, attributed to the high-level use of day-care nurser-
ies and pre-school facilities [48,55,56].
Hospitalisations and complications from varicella
While usually self-limiting, a case of varicella can develop
potentially serious complications (estimated in approxi-
mately 2 to 6% of cases attending a general practice; Addi-
tional file 2) [35,57,58]. Common complications in
individuals hospitalised with varicella include superinfec-
tion of the skin, respiratory complications and neurologi-
cal manifestations (for example, cerebellitis and
encephalitis) [21,30,32,36,41]. Although seldom
reported, long-term (including permanent or possible
permanent) sequelae, which include severe scarring,
ataxia/coordination disorder, epilepsy and cerebral nerve
paralysis, occur in 0.4 to 10.1% of patients hospitalised
for varicella (Additional file 2) [20,21,36].
In the European studies identified, the incidence of hospi-
talisation for varicella ranged from 1.3 to 4.5 per 100,000
population/year [24,27-29,43] and 12.9 to 28.0 per
100,000 children ≤ 16 years/year [17,20,21,32,42], with
an average duration of hospital stay ranging from 3 to 8
days (Additional file 2) [19,20,22,24,27,30,33-35,42,43].
Most complications and hospitalisations for varicella
occurred in children who were immunologically healthy
with no underlying medical conditions [20,23].
Deaths from varicella
Occasionally, complications of varicella can be fatal; mor-
tality rates from identified European studies are shown in
Table S1 (Additional file 1) [17-31]. Of 13 varicella-
related deaths reporting in children aged 9 months to 9
years, during the 2006 to 2007 varicella season in Eng-
land, Scotland and Wales, 12 occurred in immunologi-
cally healthy children [59]. Eight children died following
catastrophic deterioration over less than 24 hours; group
A streptococcal sepsis was confirmed in five children and
Staphylococcus aureus sepsis in two children [59]. Other
potentially fatal complications of varicella in children
include pneumonia and myocarditis [60].
The risk of death from varicella is much higher (25- to
174-fold) in adults than in children [17,61]. As in chil-
dren, the majority of adult deaths from varicella occur in
previously healthy individuals, although underlying med-
ical conditions, often immune suppression, contribute to
a fatal outcome in some cases [17].
Varicella during pregnancy
Varicella is a serious infection in pregnancy, estimated to
affect about 2,000 pregnancies each year in the UK [62]. If
left untreated, pregnant women are at greater risk of varicella
pneumonia (occurring in about 9% of pregnant women
with varicella) [63]. Varicella may also cause complications
in the infant caused by intrauterine infection with VZV via
placental transmission at any stage of pregnancy. Intrauter-
ine infection of the foetus in the early stages of development
may result in congenital varicella syndrome (an incidence of
about 2% after maternal varicella in the first 20 weeks of ges-
tation [64]), characterised by skin lesions with a dermatomal
distribution, neurological defects, ocular disease and skeletal
abnormalities [64]. If the mother develops a varicella rash
during the period from 4 days before to 2 days after delivery
the infant is at risk of neonatal varicella [65]. If left untreated,
generalised neonatal varicella can lead to death in about
20% of cases. The serious consequences of varicella during
pregnancy and the increased risk of herpes zoster for the
child can be minimised by appropriate diagnosis and by
using currently available immunoprophylactic and thera-
peutic interventions [66].
Herpes zoster
Following primary infection with VZV, the virus enters a
period of latency within the dorsal root ganglia of the
nervous system. The latent virus can be reactivated with
neuronal transfer to the skin manifesting as herpes zoster.
The mechanism of VZV reactivation is poorly understood,
but several potential risk factors have been identified [67].
The incidence of herpes zoster increases sharply from 50
to 60 years of age, increasing into later life [68]. Although
several studies have shown higher rates of reactivation in
immunocompromised patients [67], recent reports sug-
gest that herpes zoster predominantly affects immunolog-
ically healthy individuals [58,69].
Initially, herpes zoster manifests as a characteristic rash
accompanied by acute pain; however, further complica-
tions occur in 21 to 48% of patients [58]. The most com-
mon and feared complication of herpes zoster is chronic
neuropathic pain, known as post-herpetic neuralgia
(PHN) [68]. PHN occurs more frequently with advancing
age and is estimated to affect half of patients with herpes
zoster aged 70 years or older [70]. It can persist for many
years and may have a profound negative effect on patient
quality of life, substantially interfering with physical,
emotional and social functioning, vitality and mental
health [68,71,72].
Current status of varicella vaccination in Europe
The clinical burden of varicella in Europe demonstrates a
medical need for prevention strategies against the disease.
However, existing recommendations for varicella vaccina-
tion in Europe vary widely between countries (Table S3 in
Additional file 1) [6,73-75].
Germany has the widest experience with varicella URV in
Europe since use of the monovalent vaccine was recom-
mended by the Ständigen Impfkommission of the RobertPage 3 of 12
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MMRV vaccine was included in the German childhood
immunisation calendar as a two-dose schedule to be used
in place of MMR and varicella vaccines at the physician's
discretion [76]. Preliminary reports are now emerging on
the impact of varicella vaccination in Germany. Data from
a nationwide sentinel surveillance system showed that
between April and September 2005, and April and Sep-
tember 2007 the average number of varicella cases
reported per physician declined from 17 to 9 cases, corre-
sponding with an increase in vaccine doses administered
from 32 to 62 doses per physician [77]. A decline in vari-
cella-related complications was also observed [77]. The
reduction in the number of varicella cases and complica-
tions was noted in all age groups, but was most pro-
nounced in infants aged 1 to 2 years. These early findings
support previous estimates from epidemiological and
economic modelling suggesting that varicella URV would
be a highly efficient strategy in Germany to reduce the
burden of varicella, resulting in benefits for both the indi-
vidual and society [78,79].
The majority of European countries with a national rec-
ommendation for varicella vaccination suggest targeted
vaccination in susceptible adolescents or high-risk groups,
such as seronegative women of childbearing age, health-
care workers, susceptible individuals with immunosup-
pressed close contacts, day-care personnel and teachers
(Table S3 in Additional file 1). However, this strategy does
not have the potential to interrupt viral transmission and,
in the past, has been far less effective in achieving high
coverage rates when compared with childhood pro-
grammes [74].
How can varicella vaccination be implemented in Europe?
Given that monovalent varicella vaccines have been avail-
able in Europe for more than 20 years, there has already
been much debate on how best to introduce varicella vac-
cination. After consideration of the issues surrounding
European varicella epidemiology, the Working Against
Varicella in Europe group (then known as EuroVar) pub-
lished a consensus statement in 2004. This statement rec-
ommended varicella vaccination for all children between
12 and 18 months of age, and to older, susceptible indi-
viduals if high coverage can be rapidly achieved [80]. The
health and economic benefits of varicella vaccination
have also been recognised by the Society of Independent
European Vaccination Experts who have recently recom-
mended that immunisation of susceptible adolescents
should be urgently implemented [74]. However, the Soci-
ety cautions that URV, preferably incorporating a two-
dose schedule, will be needed to finally reduce the burden
of varicella disease. The dramatic reduction in varicella
morbidity and mortality rates observed in the USA follow-
ing varicella URV has also led some experts to suggest that
a universal varicella vaccination policy may be most
appropriate for Europe, not just for the medical benefits
that it would provide, but also for its social and economic
advantages [81].
The long-awaited availability of MMRV vaccines has rein-
itiated discussions on how varicella vaccination can be
implemented. The EuroVar consensus statement recog-
nised that high coverage rates for varicella vaccination are
more likely to be achieved if the vaccine was combined
with the existing measles-mumps-rubella (MMR) vaccine
(that is, as a tetravalent MMRV vaccine) [80]. Indeed,
EuroVar stated that the MMRV vaccine will not only
enhance the implementation of varicella URV, but repre-
sents the way forward, providing a more convenient
method of administration of the vaccine to children. Since
2006, two MMRV vaccines have been licensed in Europe –
Priorix-Tetra™ and ProQuad®. Both vaccines are immuno-
genic with similar reactogenicity profiles compared with
established MMR and varicella vaccines [82,83].
Varicella universal routine vaccination vs. no vaccination
In countries where varicella URV has been implemented,
it has proven a highly effective strategy for reducing the
number of varicella cases, hospitalisations, ambulatory
visits and deaths [11,84,85]. Using German epidemiolog-
ical data from an age-structured dynamic infectious dis-
ease model (based on a birth cohort of 800,000
individuals), the likely consequences of delaying deci-
sions on varicella vaccination for 1 year are 739,000 cases
of varicella, 39,720 complicated cases, 5,740 hospitalisa-
tions and 22 deaths [86].
Routine childhood varicella vaccination vs. adolescent/
adult varicella vaccination
Vaccination of susceptible adolescents from age 11 to 12
years onwards is an attractive option for healthcare payers.
This strategy can prevent the elevated morbidity and mor-
tality of varicella in older age groups, create a cohort of
individuals less likely to develop herpes zoster later in life,
mitigate the theoretical increase in herpes zoster with vari-
cella URV and minimise the risk of a potential upward
age-shift on the peak incidence of the disease (discussed
later) [74]. It could also reduce the risk of congenital vari-
cella syndrome and neonatal varicella by protecting
women of childbearing age [74]. In some areas of South-
ern Europe, it has been suggested that vaccination of ado-
lescents could be based on a negative history for varicella
in place of serological testing for varicella antigens, thus
minimising the cost of this strategy [52]. For example, in
Greece, where a high proportion of adolescents (21.5%)
are still susceptible to varicella, a self-reported history was
reported to have a high negative predictive value (73.5%),
except in adolescents with household exposure to VZV
[52].Page 4 of 12
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cination strategy. Adolescents, as a group, do not rou-
tinely visit a physician and coverage achieved for vaccines
recommended in this age group is generally low [87].
Varicella vaccination uptake in adolescents could be
improved in some countries by catch-up programmes
(that is, opportunistic vaccination). However, this
approach may not work well in countries that do not
include varicella vaccine in the national immunisation
calendar as physicians will not be familiar with the vac-
cine.
An adolescent vaccination strategy is likely to be benefi-
cial from an individual's perspective, estimated to prevent
around 5% of varicella cases, 5% of complications, 8% of
hospitalisations and 9% of deaths from varicella (assum-
ing vaccination of 11 to 12 year-olds, with coverage rising
from 10% to 30% over the first 5 years of a vaccination
programme) [88]. However, from a societal perspective,
an adolescent strategy would have minimal effect on
transmission of VZV and no benefit in the youngest
infants (that is, younger than 1 year of age with a high risk
of complications post-varicella) [74]. A universal child-
hood varicella immunisation programme implemented
in such a way that a high coverage rate is achieved [88],
could address these issues and would have maximal
impact on disease epidemiology, as has been demon-
strated from data in the USA and Uruguay [11,85,89,90].
Monovalent varicella vaccination vs. tetravalent MMRV 
vaccination of infants and children
MMRV vaccines avoid the need for an additional injection
when vaccinating against measles, mumps, rubella and
varicella, which is beneficial for the majority of European
countries that have an already crowded vaccination sched-
ule and where administration of more than two vaccines
in a single visit is usually not acceptable to parents or car-
ers. URV with MMRV vaccines is likely to rapidly improve
the uptake of varicella vaccination, in line with the cover-
age expected for MMR vaccines, thus maximising herd
immunity and reducing the risk of an upward shift in the
peak age of varicella disease. In addition to these benefits,
two doses of MMRV vaccine will naturally facilitate a two-
dose varicella vaccination schedule. MMRV vaccines are
used in several countries such as the USA, Germany and
Australia, and data demonstrating their effectiveness are
eagerly awaited.
The recommendation by the USA Advisory Committee on
Immunization Practices (ACIP) for two doses of varicella-
containing vaccine as part of routine childhood immuni-
sation, officially adopted in 2007, stated a preference for
MMRV vaccines over the component MMR and varicella
vaccines [10]. However, ACIP removed the preference for
the combination MMRV vaccine in 2008 [91], in response
to new data from surveillance by the Centers for Disease
Control (CDC) and Merck for ProQuad® in the USA. These
data suggested that the risk of febrile seizures in the 5 to
12 days after vaccination with the first dose of MMRV is
higher than with separately administered MMR and vari-
cella vaccines [92]. Of note, febrile seizures are typically of
short duration (< 15 minutes) and resolve without seque-
lae. Furthermore, the USA Food and Drug Administration
continue to be satisfied with the safety and efficacy of
MMRV vaccine, having not made any changes to its indi-
cations for use and stating that the benefits of using the
vaccine continue to outweigh the risks [93]. The situation
with regard to MMRV vaccination and febrile seizures
continues to be monitored closely. Data are not yet avail-
able for GlaxoSmithKline's MMRV vaccine and it is cur-
rently unclear what these data may show; the two vaccines
differ in terms of measles and varicella dose.
A third option for introduction of varicella vaccination
that may be considered by policy makers is to administer
the first doses of MMR and varicella vaccines separately,
followed by a second dose of combined MMRV vaccine at
least 4 weeks later [94,95]. This strategy may mitigate any
perceived increase in reactogenicity following the first
dose of MMRV vaccine.
Two doses of varicella vaccine vs. one dose for universal 
routine vaccination
Two doses of varicella vaccine as part of the USA child-
hood immunisation programme have been officially rec-
ommended by the ACIP since 2007 [10]. Regulatory
approval of MMRV vaccines by the European Medicines
Agency also recognises that a second dose of a varicella-
containing vaccine ensures maximal protection against
the disease [96]. In Europe, two doses of varicella vaccine
are recommended in Greece (Table S3 in Additional file
1) and by the Spanish Association of Pediatrics (although
this has yet to be officially adopted by the national
authorities [97]), and in Germany, MMRV vaccine can be
used, resulting in two doses of varicella being given.
Countries considering varicella URV (with monovalent or
combined vaccines) have the opportunity to evaluate the
merits of a one- or two-dose schedule. In the USA, after a
rapid decline in varicella incidence following the intro-
duction of a one-dose vaccination strategy from 1995, the
number of cases at CDC surveillance sites reached a pla-
teau in 2002. This occurred despite continued high rates
of vaccination coverage [98]. Furthermore, outbreaks of
breakthrough varicella (that is, a case of varicella occur-
ring 42 days or more after vaccination following exposure
to wild-type virus) continued to occur among immunised
children in day-care centres and schools (see recent review
by Seward et al.) [99]. Most studies in this review showed
a varicella vaccine effectiveness of 80 to 89% after onePage 5 of 12
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did not respond to vaccination (primary immune failure)
or who experienced waning immunity over time (second-
ary immune failure) [100]. Two doses of varicella vaccine
have been associated with higher vaccine efficacy in clini-
cal studies and the projected risk of breakthrough disease
over 10 years is three times lower than among individuals
who received one dose [101]. Humoral and cell-mediated
responses were also greater after two doses of varicella vac-
cine, suggesting improved vaccine efficacy compared with
one dose [102,103].
The interval between two doses of varicella vaccine 
(monovalent or MMRV)
Depending on the product used, the first dose of monova-
lent varicella vaccine or MMRV vaccine can be adminis-
tered from the age of 9 or 12 months. The second dose is
then administered according to an 'accelerated', 'standard'
or 'longer' schedule in accordance with local recommen-
dations. The schedules currently used for MMR vaccines
are shown in Table S3 (Additional file 1) [104]. Each strat-
egy is associated with specific benefits and challenges,
which are discussed below. For the MMRV vaccine, only
the varicella component is discussed – there may be differ-
ent benefits and challenges for the measles, mumps and
rubella components.
Accelerated schedule: dose 1 at 11 to 23 months and dose 
2 at 12 to 24 months
An accelerated schedule means that the two vaccine doses
are administered close together (at least 1 month apart;
during second year of life for MMR(V) vaccines). This
schedule is used for MMR vaccines in Europe in the Czech
Republic, Austria, France, Germany and Switzerland
[104], and for MMRV vaccines in Germany (Table S3 in
Additional file 1) [76]. In the USA, although the recom-
mended timing of the second dose is 4 to 6 years of age,
this remains flexible, permitting an accelerated schedule
[10], and it is also allowed by the WHO for measles-con-
taining vaccines depending on the local programmatic
and epidemiological situation [105].
Administering two doses of varicella-containing vaccine with
a short interval provides the opportunity to enhance compli-
ance, and hence vaccine coverage because 2-year-old or
younger children are more accessible to healthcare profes-
sionals than older age groups. After one dose of vaccine, the
risk of breakthrough varicella increases with time. Adminis-
tering MMRV vaccines according to an accelerated schedule
therefore allows high levels of immunity to vaccine antigens
to be established early in life, ensuring that, if primary vac-
cine failure occurs, a child does not remain unprotected for
2 to 12 years (standard and longer schedules).
Clinical studies of varicella and MMRV vaccines show
robust and persistent immune responses when two doses
are administered according to an accelerated schedule
[82,83,101,106]. In one study, in which children were
randomised to receive either two doses of MMRV vaccine
(Priorix-Tetra™; MMRV group) or one dose of MMR vac-
cine (Priorix™) concomitantly with varicella vaccine (Var-
ilrix™) followed by another MMR vaccination 6 to 8 weeks
apart (MMR+V group) [82], seropositivity rates for vari-
cella after 3 years were 99.4% (MMRV group, N = 225)
and 96.8% (MMR+V group, N = 79) [106]. Over the 3-
year follow-up period (total vaccinated cohort N = 494),
two mild varicella breakthrough cases were reported in
the MMRV group and four mild and one moderate case in
the MMR+V group [106]. No studies evaluating the
immune response of two doses of Merck's MMRV vaccine
administered according to an accelerated schedule could
be identified.
Standard schedule: dose 1 at 12 to 24 months and dose 2 
at 3 to 7 years
A standard schedule with an interval of 1 to 6 years is used
for administration of MMR vaccines in the majority of
countries in Europe (Table S3 in Additional file 1). In
some countries, such as Finland, excellent coverage has
been achieved with both vaccine doses, which would be
beneficial for varicella vaccination should MMR vaccines
be replaced with MMRV vaccines [107]. As for the acceler-
ated schedule, a robust immune response was measured
to the second dose of MMRV vaccine given to children at
5 to 6 years [108].
A potential drawback of the standard schedule is the risk
of breakthrough disease during the longer interval
between vaccine doses. One dose of varicella vaccine was
shown to be 80 to 85% effective in a number of field stud-
ies, which is not sufficient to prevent outbreaks and inter-
rupt viral transmission [99]. Thus, in the intervening 1 to
6-year period between the two doses, breakthrough cases
of varicella can be expected, which could result in out-
breaks in close communities such as day-care centres and
schools, and cases in susceptible adolescents and adults.
However, given the potential scheduling challenges with
administering the vaccine according to an accelerated
schedule (for example, crowded vaccination calendars
during the first 2 years of life), the standard schedule
offers an effective alternative.
Longer schedule: dose 1 at 12 to 18 months and dose 2 at 
8 to 13 years
Several countries administer MMR vaccines according to a
longer schedule, which means that the two doses are given
7 to 12 years apart (Table S3 in Additional file 1). Admin-
istering the second dose of varicella-containing vaccine
with a long interval is likely to reduce the risk of waning
immunity to vaccine antigens resulting in infection into
adolescence and adulthood, when the disease can be
more severe [100]. However, as was seen from experiencesPage 6 of 12
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cine doses may prevent elimination of varicella. Despite
this potential drawback, countries may be hesitant about
changing an established longer schedule for fear of a neg-
ative impact on vaccine uptake.
Why has varicella vaccination been delayed in Europe?
There are positive effects of universal childhood varicella
vaccination on disease incidence, and the rate of compli-
cations and hospitalisations [84]. Given these benefits, it
is curious why more countries in Europe have not intro-
duced the varicella vaccine into national immunisation
schedules. The possible reasons for this are considered in
brief below.
Lack of recognition of varicella as a serious disease
As noted previously, appreciation of the true burden of
varicella can be hampered because varicella is not a noti-
fiable disease in many countries, and there appears to be
a degree of underreporting to mandatory notification sys-
tems. A lack of awareness about the potential complica-
tions of varicella means that the disease continues to be
perceived as benign by many physicians and parents.
The available reports of the varicella burden in European
countries indicate that children can experience complica-
tions of this disease, which may require hospitalisation,
and occasionally can be fatal. Communication of varicella
outbreaks, such as the large outbreak in the UK in April
2007, may be beneficial in raising awareness of the dis-
ease among parents, physicians and public health offi-
cials.
Perception of age shift with varicella vaccines
A concern exists that widespread childhood varicella vac-
cination may produce an upward shift in the peak age of
the disease to older individuals, for whom varicella may
be more severe. In the USA there has, as anticipated, been
a rise in the age of peak incidence of the disease following
the widespread introduction of varicella vaccination with
a one-dose schedule. Before 1995, around 73% of vari-
cella cases occurred in children aged 6 years or younger,
with a peak disease frequency between 3 and 6 years
[100]. In 2004, on the other hand, children aged 6 years
and younger accounted for only 30% of varicella cases
[100]; disease frequency peaked in vaccinated children
(one dose) between the ages of 6 and 9 years and in
unvaccinated children between the age of 9 and 12 years
[100]. However, the absolute number of cases in older
children remained similar to that reported in the pre-vac-
cination era. Conversely, since URV implementation there
has been a decline in the age-specific hospitalisation or
varicella incidence rates in all age groups (including
infants not eligible for vaccination and adults)
[11,90,109]. This observation is most likely explained by
herd immunity, where high coverage rates interrupt viral
transmission, indirectly protecting those who are not vac-
cinated.
Perception of an increase in herpes zoster
A number of sources indicate that boosting of immunity to
VZV can reduce the incidence of herpes zoster [67,110]. A
case-control study suggested that exogenous exposure to
VZV via contact with children protects individuals with
latent VZV infection against herpes zoster by boosting
immunity [111]. Statistically significant protection (odds
ratio 0.29 (95% confidence interval: 0.10 to 0.84)) was
achieved for those adults with five or more contacts with
VZV during the past 10 years [111]. This type of data led to
formulation of the hypothesis that a reduction of child-
hood varicella by vaccination might lead to increased inci-
dence of herpes zoster in adults [110]. Using mathematical
modelling, Brisson et al proposed that routine varicella vac-
cination of children will produce a substantial increase in
the rates of herpes zoster over the first 30 to 50 years after
vaccination is introduced [110]. In the longer term, under
the assumptions of the model, a vaccination programme
that eliminates varicella will also eliminate herpes zoster
[110]. To date, the majority of studies conducted in coun-
tries where the incidence of varicella has been reduced by
vaccination have not shown an accompanying increase in
herpes zoster [84,109,112,113].
Evidence from different sources suggests that varicella vac-
cination may be associated with a reduced incidence, and
hence lower risk, of herpes zoster in vaccinees [113-116].
In a 10 to 26-year follow-up of individuals vaccinated as
healthy young adults, the herpes zoster incidence was
0.91/1,000 person-years, lower than the rates quoted by
the authors for unvaccinated individuals (2.15 to 4.05
cases/1,000 person-years) [113]. Furthermore, children
with leukaemia (who have a naturally increased risk of
herpes zoster), who were vaccinated with one dose of vari-
cella vaccine, had a lower incidence of herpes zoster than
children with leukaemia who contracted VZV naturally
(crude incidence rates of 8.0 vs. 24.6/1,000 person-years,
respectively; P = 0.01) [114].
Available data support the hypothesis that vaccination
may reduce viral latency and thus the incidence of herpes
zoster by minimising infection of the skin (that is, the
development of varicella lesions) [115], which is thought
to be directly related to the establishment of VZV latency
[114,115].
In summary, the childhood vaccination programme
should reduce the risk of herpes zoster in vaccinees in the
longer term. Furthermore, if needed, appropriate action
can be taken (for example, implementation of a herpes
zoster vaccine in adults).Page 7 of 12
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If varicella vaccination is to be implemented using MMRV
vaccines, the existing coverage for MMR vaccines may
need to be considered. The WHO recommendations state
that coverage rates for varicella vaccination should exceed
85% in order to avoid an upward age-shift in the peak
incidence of varicella disease. In European Union coun-
tries in 2006, coverage for measles-containing vaccine
ranged from 82% to 98% for the first dose, with 18 of 20
countries with data available reporting coverage rates to
the WHO exceeding 85% [117]. For the second dose, vac-
cine coverage ranged from 60 to 98%, with 11 of 14 coun-
tries reporting coverage rates to the WHO exceeding 85%
[117]. Therefore, the majority of European countries with
data available reach the stated threshold of 85% coverage
with MMR vaccines, and thus could be considered suita-
ble for implementation of MMRV vaccines.
Cost (country-specific)
The cost of vaccination is relevant for public health offi-
cials and individuals purchasing vaccines on the private
market, and is country-specific. European countries apply
different models for production of guidelines, and for
linking these to funding, but cost-effectiveness is becom-
ing a standard requirement. In some countries, such as the
UK and France, only costs from a healthcare perspective
are taken into account when considering the cost-effec-
tiveness of vaccination – all societal costs (for example,
work-time lost) are excluded from the analysis.
In Germany, findings from a mathematical model suggest
that varicella URV with a one-dose schedule will provide
essential clinical benefits for individuals, and that signifi-
cant economic benefits can also be expected [35]. Further-
more, an updated version of this model has assessed the
direct and indirect cost-savings associated with two doses
of varicella vaccine and MMRV vaccination compared
with an adolescent immunisation strategy with one dose
of varicella vaccine [118]. The model demonstrated that
two doses of MMRV vaccine are cost-saving from a societal
and a health system perspective (benefit-cost-ratios [BCR]
of 2.56 and 1.08, respectively) [118]. Using the same
model, varicella URV with a two-dose schedule was pre-
dicted to be highly effective for reducing the burden of
varicella disease in Italy, with significant net savings from
the societal perspective, but was not cost-saving from the
National Health Service perspective in the majority of sit-
uations analysed [119].
The latest study results from the USA demonstrated that,
compared with no intervention, the two-dose regimen is
cost-saving from a societal perspective (BCR = 2.73)
(assuming that 30% of children would receive MMRV vac-
cine as a first dose and 100% would receive MMRV as a
second dose, and using 2006 prices) [120]. Furthermore,
the economic benefit of the two-dose MMRV regimen
compares very favourably with other medical interven-
tions. However, the authors note that compared with one-
dose URV, the two-dose MMRV regimen did not produce
additional savings from a societal perspective (BCR =
0.56). Notably, however, additional factors such as the
cost associated with outbreaks following one-dose URV
were not included in the model.
A favourable BCR does not necessarily result in public
funding of a vaccine. New vaccines entering the market
compete for a share of a limited healthcare budget; in
recent years, state-of-the-art vaccines against Streptococcus
pneumoniae, human papilloma virus and rotavirus have
commanded a great deal of public attention and, in some
countries, have been prioritised over varicella vaccination.
Summary
Despite European recommendations for varicella vaccina-
tion, VZV continues to cause a high number of varicella
cases, potentially requiring medical visits or hospitalisa-
tions and occasionally leading to long-term sequelae or
even death. The majority of varicella complications occur
in healthy children, meaning that it is not possible to pre-
dict who will be affected.
With the exception of Germany and Greece, most Euro-
pean countries have delayed the introduction of varicella
vaccination into the national immunisation schedule.
However, with many concerns about the vaccine remain-
ing hypothetical and the new opportunities offered by
MMRV vaccines, reassessment may be timely.
Accumulating evidence from countries that have imple-
mented universal varicella vaccination of infants demon-
strates a dramatic reduction in the burden of varicella,
thus providing the strongest support for widespread
implementation of the WHO recommendation for vari-
cella vaccination in European countries.
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